TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23353795

Group type: EXPERIMENTAL
Intervention: Limb RIPC
Number of subjects: 62
Study: 21331977

Group type: EXPERIMENTAL
Intervention: Long-term psychotherapy
Number of subjects: 0
Study: 19709851

Group type: EXPERIMENTAL
Intervention: 14-session standard CBT (n=33)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 14-session group CBT (n=35)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 7-session brief CBT (n=32)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 100
Study: 17095725

Group type: EXPERIMENTAL
Intervention: Rho kinase inhibitor, fasudil
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 14707020

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 11342364

Group type: EXPERIMENTAL
Intervention: CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) chemotherapy protocol
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: CEMP chemotherapy protocol
Number of subjects: 139
Study: 9385232

Group type: EXPERIMENTAL
Intervention: Semi Fowler position
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30 degrees laterally inclined position
Number of subjects: 26

Group type: COMPARATOR
Intervention: 90 degrees side lying position
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Polyethylene‐urethane mattress
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 26
Study: 7936476

Group type: EXPERIMENTAL
Intervention: Lisinopril (10mg, 20mg, 40mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Captopril (25mg, 50mg, 100mg daily)
Number of subjects: 24
Study: 2847567

Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of ethanol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.1 ml/kg of ethanol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14155162

Group type: EXPERIMENTAL
Intervention: Methysergide (2 mg, three times a day orally for 5 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (identical dosage and duration as methysergide)
Number of subjects: 13
Study: 31286645

Group type: EXPERIMENTAL
Intervention: TRV734 125 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRV734 125 mg (drug in capsule after high-fat meal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRV734 (various doses 2 to 250 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRV734 (various doses)
Number of subjects: 0
Study: 31596672

Group type: EXPERIMENTAL
Intervention: Type I recurrence (single recurrence in remnant kidney or ipsilateral renal fossa)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Type II recurrence (single recurrence in ipsilateral vasculature, ipsilateral adrenal gland, or lymph node)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Type III recurrence (single recurrence in other intra-abdominal soft tissues or organs)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Type IV recurrence (any combination of Types I-III, or multiple recurrences within a single Type)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Five-year cancer-specific survival
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Five-year overall survival
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Types I-III recurrences
Number of subjects: 300
Study: 29178955

Group type: EXPERIMENTAL
Intervention: Non-descent vaginal hysterectomy (NDVH)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 147
Study: 26151924

Group type: EXPERIMENTAL
Intervention: DHA (1470 mg/day) + EPA (147 mg/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 23541756

Group type: EXPERIMENTAL
Intervention: ISIS 333611 (0.15 mg, 0.50 mg, 1.50 mg, 3.00 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ISIS 333611
Number of subjects: 32
Study: 16573261

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1% metronidazole cream
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: metronidazole creams
Number of subjects: 32

Group type: COMPARATOR
Intervention: petrolatum (negative control)
Number of subjects: 32
Study: 14613285

Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation (two 1.5-hour sessions)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Print materials about disability employment issues and resources by mail (Control)
Number of subjects: 242
Study: 8746863

Group type: EXPERIMENTAL
Intervention: Intense multidisciplinary management
Number of subjects: 333
Study: 1936348

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste and mouthrinsing
Number of subjects: 44

Group type: COMPARATOR
Intervention: NaF toothpaste and mouthrinsing
Number of subjects: 44
Study: 6214216

Group type: EXPERIMENTAL
Intervention: Abrasive cleaner
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cleansing agent without abrasive granules
Number of subjects: 44
Study: 29206921

Group type: EXPERIMENTAL
Intervention: 600 mg modafinil
Number of subjects: 22

Group type: COMPARATOR
Intervention: 60 mg methylphenidate
Number of subjects: 22

Group type: COMPARATOR
Intervention: 125 mg 3,4‐methylenedioxymethamphetamine
Number of subjects: 22
Study: 28212471

Group type: EXPERIMENTAL
Intervention: Ketorolac and nifedipine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ketorolac and tamsulosin
Number of subjects: 150
Study: 26374918

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional diuretic therapy
Number of subjects: 0
Study: 23349882

Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNB) treatment
Number of subjects: 88
Study: 21592048

Group type: EXPERIMENTAL
Intervention: 2 mg RSG XR
Number of subjects: 2981

Group type: EXPERIMENTAL
Intervention: 8 mg RSG XR
Number of subjects: 2981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2981
Study: 18708299

Group type: EXPERIMENTAL
Intervention: sLORETA
Number of subjects: 0
Study: 16175957

Group type: EXPERIMENTAL
Intervention: Apartment-based breast cancer education program
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 345
Study: 12840087

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous peripheral-blood hematopoietic progenitor-cell transplantation (6 g of cyclophosphamide, 480 mg of thiotepa, 1600 mg of carboplatin)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (FEC every three weeks for five courses)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy in patients with 10 or more positive nodes
Number of subjects: 885

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy in patients with 10 or more positive nodes
Number of subjects: 885
Study: 11043056

Group type: EXPERIMENTAL
Intervention: Leflunomide (loading dose of 100 mg orally for three days, followed by 20 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate or sulphasalazine (previous treatments)
Number of subjects: 0
Study: 9091856

Group type: EXPERIMENTAL
Intervention: Cuprophan dialysis membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polysulfone dialysis membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polysulfone membranes
Number of subjects: 10
Study: 2069245

Group type: EXPERIMENTAL
Intervention: Epidural pethidine 25 mg in normal saline
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normal saline alone (control)
Number of subjects: 94
Study: 7092423

Group type: EXPERIMENTAL
Intervention: Prescribed, supervised exercise training program
Number of subjects: 651

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 651
Study: 31001692

Group type: EXPERIMENTAL
Intervention: EASE (Emotion And Symptom-focused Engagement)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 42
Study: 31422065

Group type: EXPERIMENTAL
Intervention: Goals of Patient Care (GOPC) process
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control (Advance Care Planning alone)
Number of subjects: 326
Study: 27633651

Group type: EXPERIMENTAL
Intervention: Multigrowth factor (MGF) cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 20
Study: 26443993

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study: 25057201

Group type: EXPERIMENTAL
Intervention: Auditory attention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual attention
Number of subjects: 0
Study: 21919966

Group type: EXPERIMENTAL
Intervention: Iloprost administered for seven days after transplantation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no iloprost treatment)
Number of subjects: 80
Study: 19180065

Group type: EXPERIMENTAL
Intervention: Usual lifestyle treatment program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Standard lifestyle treatment program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle treatment program
Number of subjects: 39
Study: 17728363

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) (1.5-2.0 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (CTX) (0.75-1.0 g/m2)
Number of subjects: 20
Study: 15678245

Group type: EXPERIMENTAL
Intervention: ANP (60 pmol/100 mL FAV/min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Short-term infusions of ANP
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Long-term infusions of ANP
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Co-infusion of ANP, BNP, and CNP
Number of subjects: 11
Study: 12661246

Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combined medicamentous prophylactics with Sandostatin and Verapamil
Number of subjects: 124
Study: 10037839

Group type: EXPERIMENTAL
Intervention: hANP administered after operation until leaving ICU
Number of subjects: 40

Group type: COMPARATOR
Intervention: No hANP administered (Control)
Number of subjects: 40
Study: 7619666

Group type: EXPERIMENTAL
Intervention: Oral dextromethorphan 30 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled dextromethorphan (1, 3, and 30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral matched placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched inhaled placebo
Number of subjects: 20
Study: 2244080

Group type: EXPERIMENTAL
Intervention: Flexible group sequential testing using a Lan and DeMets procedure with permutation test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stochastic curtailment ideas
Number of subjects: 0
Study: 736254

Group type: EXPERIMENTAL
Intervention: 1:1000 Adrenaline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5% Cocaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10% Cocaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5% Cocaine/1:1000 Adrenaline
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5% Cocaine, 10% Cocaine, 5% Cocaine/1:1000 Adrenaline
Number of subjects: 100
Study: 31518355

Group type: EXPERIMENTAL
Intervention: Y-PATH intervention (whole school intervention including teacher, parent, and PE components)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 564
Study: 28327453

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation plus active oxybutynin administration
Number of subjects: 66

Group type: COMPARATOR
Intervention: Active oxybutynin administration
Number of subjects: 66

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 66
Study: 25062908

Group type: EXPERIMENTAL
Intervention: Physiotherapy for acute WAD
Number of subjects: 20
Study: 23809430

Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise (NHE)
Number of subjects: 18
Study: 22283027

Group type: EXPERIMENTAL
Intervention: Human recombinant lactoferrin for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19419331

Group type: COMPARATOR
Intervention: Standard caspofungin regimen (50 mg/day after a 70 mg dose on day 1)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: High-dose caspofungin regimen (150 mg/day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard caspofungin regimen
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: High-dose caspofungin regimen
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 204
Study: 16782716

Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) combined with substrate modification (SM)
Number of subjects: 62
Study: 15496641

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice weekly)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice weekly) plus Methotrexate (weekly oral dose, median 20 mg)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control group (Methotrexate alone not specified)
Number of subjects: 682
Study: 11778664

Group type: EXPERIMENTAL
Intervention: 2,3-dimercapto-1-propanesulfonate 100-mg capsules 4 times a day for 1 week, repeated in the 3rd, 5th, and 7th week
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo capsules resembling 2,3-dimercapto-1-propanesulfonate
Number of subjects: 21
Study: 9102259

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for colon carcinoma
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for rectal carcinoma
Number of subjects: 39
Study: 8385284

Group type: EXPERIMENTAL
Intervention: Nifedipine retard 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 10
Study: 3511766

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia (freezing of the ilioinguinal nerve)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No cryoanalgesia (control group)
Number of subjects: 36
Study: 29345113

Group type: EXPERIMENTAL
Intervention: Parents-only intervention group (n=89)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Parents-and-child intervention group (n=84)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Follow-up alone control group (n=74)
Number of subjects: 247

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 247
Study: 27571269

Group type: EXPERIMENTAL
Intervention: Intervention formula with equal amounts of AA and DHA (IF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control formula without additional AA and DHA (CF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast milk (BM)
Number of subjects: 0
Study: 23813124

Group type: EXPERIMENTAL
Intervention: Self-monitoring sleep diary and response inhibition training
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Sleep diary only
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control questionnaire
Number of subjects: 190
Study: 22278627

Group type: EXPERIMENTAL
Intervention: Daily dialysis for 1 week after standard hemodialysis (HD) for 1 week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard hemodialysis (HD) for 1 week after daily dialysis for 1 week
Number of subjects: 60
Study: 20507582

Group type: EXPERIMENTAL
Intervention: Combined screening program for AAA, PAD, and hypertension
Number of subjects: 50000
Study: 18778208

Group type: EXPERIMENTAL
Intervention: Symphony breast pump (SBP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Classic breast pump (CBP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single-phase suction pattern in SBP
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiphase suction pattern in SBP
Number of subjects: 100
Study: 15667660

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Doxycycline (10 and 100 microg/ml) - ex-vivo treatment
Number of subjects: 14
Study: 12195131

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 10429624

Group type: EXPERIMENTAL
Intervention: SSG II protocol
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: SSG VIII protocol
Number of subjects: 223

Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 223
Study: 7594338

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 30 mg q.d. for 8 weeks in GU and 6 weeks in DU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Roxatidine (R) 75 mg b.i.d. for 8 weeks in GU and 6 weeks in DU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Roxatidine (R)
Number of subjects: 0
Study: 2135068

Group type: EXPERIMENTAL
Intervention: Actovegin (250 ml 20%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (250 ml)
Number of subjects: 0
Study: 6107452

Group type: EXPERIMENTAL
Intervention: oxprenolol, 40 mg three times a day
Number of subjects: 473

Group type: COMPARATOR
Intervention: disopyramide phosphate, 150 mg three times a day
Number of subjects: 473
Study: 6306388

Group type: COMPARATOR
Intervention: HCTZ 50 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MK-421 10 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HCTZ 50 mg/day plus MK-421 10 mg/day
Number of subjects: 18
Study: 31185057

Group type: EXPERIMENTAL
Intervention: Park Prescription intervention including face-to-face counseling and weekly structured exercise sessions in the park.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Structured exercise sessions on weekday evenings or weekend mornings.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Strategies to increase physical activity in parks.
Number of subjects: 97
Study: 29279010

Group type: EXPERIMENTAL
Intervention: Positive symptoms
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Disorganisation symptoms
Number of subjects: 81
Study: 27711083

Group type: EXPERIMENTAL
Intervention: WBRT plus vandetanib (100 mg once daily for 3 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo with WBRT (30 Gy in 10 fractions)
Number of subjects: 24
Study: 24702135

Group type: EXPERIMENTAL
Intervention: CTR+HR
Number of subjects: 12

Group type: COMPARATOR
Intervention: CTR
Number of subjects: 12
Study: 22226086

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg QD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg BID
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 20409057

Group type: EXPERIMENTAL
Intervention: Case management intervention (conducted by two nurses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 17652648

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg per kilogram of body weight)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 16232039

Group type: EXPERIMENTAL
Intervention: Instructions focused on the Internet's information tools
Number of subjects: 117

Group type: COMPARATOR
Intervention: Instructions focused on the Internet's communication tools
Number of subjects: 117

Group type: COMPARATOR
Intervention: Basic instructions about how to use the Internet
Number of subjects: 117
Study: 12387530

Group type: EXPERIMENTAL
Intervention: Home-made oral supplement (group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Home-made oral supplement (group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 66
Study: 10460068

Group type: EXPERIMENTAL
Intervention: Initial intravenous dose of 50 mg ranitidine; followed by either repeated injections (50 mg every 6 hours) or a continuous infusion (50 mg plus 0.125 mg/kg/h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 8528053

Group type: EXPERIMENTAL
Intervention: 60 micrograms/m2
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 125 micrograms/m2
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 250 micrograms/m2
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Higher dose groups
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: All dose groups
Number of subjects: 61
Study: 2192011

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (1.5 x 10(6) IU) injected intralesionally plus podophyllin resin applied topically once weekly for 3 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Podophyllin alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b plus podophyllin
Number of subjects: 97
Study: 380730

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 14
Study: 31560067

Group type: EXPERIMENTAL
Intervention: Borrelia burgdorferi seropositivity (Bb+)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Borrelia burgdorferi seronegativity (Bb-)
Number of subjects: 689
Study: 31856760

Group type: EXPERIMENTAL
Intervention: Naloxone (0.05 μg·kg−1·h−1)
Number of subjects: 69
Study: 28893201

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 8 cm H2O
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 10 cm H2O
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 12 cm H2O
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 14 cm H2O
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 16 cm H2O
Number of subjects: 90
Study: 28327481

Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised exercises
Number of subjects: 140

Group type: COMPARATOR
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 140